Tango's vopimetostat plus daraxonrasib combo shows 92% response rate in pancreatic cancer

Tango Therapeutics announced positive Phase 1/2 data showing a combination of its PRMT5 inhibitor vopimetostat and Revolution Medicines' RAS inhibitor daraxonrasib achieved 92% objective response rate in MTAP-deleted pancreatic cancer patients, with 90% maintaining progression-free survival at 6 months. The company plans to advance the combination into Phase 3 development, potentially offering a chemotherapy-free treatment option for first-line pancreatic cancer.